A randomised, double-blind, placebo controlled, crossover dose-ranging study to investigate the effect of rosuvastatin (CRESTOR) on high density lipoprotein kinetics in patients with the metabolic syndrome

Trial Profile

A randomised, double-blind, placebo controlled, crossover dose-ranging study to investigate the effect of rosuvastatin (CRESTOR) on high density lipoprotein kinetics in patients with the metabolic syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2008

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Metabolic syndrome
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Aug 2008 Results have been published in Diabetes Care.
    • 06 Dec 2006 Status change
    • 23 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top